Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2017 December;61(4) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2017 December;61(4):438-46

CURRENT ISSUE
 

ARTICLE TOOLS

Publication history
Reprints
Cite this article as

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,481


eTOC

 

ORIGINAL ARTICLE  


The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2017 December;61(4):438-46

DOI: 10.23736/S1824-4785.17.02792-3

Copyright © 2015 EDIZIONI MINERVA MEDICA

language: English

18F-FDG PET/CT is useful in initial staging, restaging for pediatric rhabdomyosarcoma

Yun DONG 1, 2, Xuemei ZHANG 3, Shaoyan WANG 1, Suyun CHEN 1, Chao MA 1

1 Nuclear Medicine, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; 2 Radiation Oncology, NO.9 People Hospital Affiliated to Shanghai Tiao Tong, University School of Medicine, Shanghai, China; 3 Department of Surgery, Linyi People’s Hospital, Linyi, Shandong, China


PDF  


BACKGROUND: This study aimed to evaluate 18F-fluordeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) as an adjunct to CT and/or magnetic resonance imaging (MRI) in the staging and follow-up of pediatric rhabdomyosarcoma (RMS).
METHODS: A total of 28 consecutive pediatric RMS (20 males, 8 females; mean age: 4.8 years, 10 embryonal, 18 alveolar), in whom FDG PET/CT was performed at staging (13 patients), to evaluate the therapeutic effects and to follow-up (15 patients), were retrospectively included. FDG PET/CT was compared with MRI or CT performed with a less than a 10-day interval for initial staging in 13 patients. Histological data and follow-up (mean, 18 months) were considered as the standard of reference for result interpretation.
RESULTS: At staging, FDG PET/CT and CT/MRI were equally effective in the detection of the primary RMS (accuracy, 100%). FDG PET/CT revealed metastases in lymph nodes, prostate, intestinal wall, chest wall and the peritoneum in 5 patients missed by CT or MRI, and found 41positive lymph node territories in 6 patients, 8 lung metastases in 3 patients and 40 lesions located in other anatomical regions (muscle, brain, etc.) in 4 patients versus 16, 6, and 29 for CT or MRI. In 4 patients (31%), modifications were made and comprised 1 local therapy change and 3 changes of systemic treatment as well. Follow-up time ranged from 3 to 48 months, with a median follow-up time of 18 months in 15 patients for evaluation of therapeutic effects. Alveolar RMS (ARMS) had significantly high SUVmax, and more metastases was found in ARMS.
CONCLUSIONS: 18F-FDG PET/CT may be useful in staging and restaging pediatric RMS, especially for assessing secondary lesions with potential therapeutic strategy alteration. The significant high SUVmax of ARMS and more metastases may indicate worse prognosis which needs further study. This study confirms that 18F-FDG PET/CT is also valuable in therapeutic assessment and follow-up.


KEY WORDS: Rhabdomyosarcoma - Pediatrics - Fluorodeoxyglucose F18 - Positron emission tomography computed tomography

top of page

Publication History

Issue published online: September 20, 2017
Article first published online: May 21, 2015
Manuscript accepted: May 18, 2015
Manuscript revised: April 21, 2015
Manuscript received: January 13, 2015

Cite this article as

Dong Y, Zhang X, Wang S, Chen S, Ma C. 18F-FDG PET/CT is useful in initial staging, restaging for pediatric rhabdomyosarcoma. Q J Nucl Med Mol Imaging 2017;61:438-46. DOI: 10.23736/S1824-4785.17.02792-3

Corresponding author e-mail

mc_7419@hotmail.com